Lilly's Garraway on his way to Roche as veteran Horning set to exit by year-end

Roche
This comes just twpo weeks after Garrway left Eli Lilly. (Roche)

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer and head of global product development at Roche in the fall.  

He will fill the large shoes left by the 10-year Roche-Genentech veteran Sandra Horning, who is retiring on the last day of this decade.

In a very brief release, the Swiss Big Pharma said that Garraway comes on board from the start of October, with the two working at the Big Pharma until December 31, when Horning officially leaves.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Garraway’s name will sound familiar as he was until very recently Eli Lilly’s SVP of oncology R&D, as well as heading up Lilly’s research laboratories novel target research. He will be based in South San Francisco.

RELATED: Eli Lilly cancer chief Levi Garraway replaced by Loxo CEO Josh Bilenker (for now) as Big Pharma rings the changes

He left unexpectedly at the start of the month “to pursue other opportunities” and it turns out it was a pretty big one.

Lilly has been working on cancer drugs and new therapies but with limited success; Roche is one of the largest oncology players on the planet with its older oncology medicines still raking in billions of dollars each year, though it now wants more of a say in the next-gen form of cancer care.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.